<Companies>
    <Company>
        <CompanyName>BioNTech</CompanyName>
        <ISIN>US0378331005</ISIN>
        <LEI>549300VJTTGNEANFBN84</LEI>
        <Forbes2022Rating>1</Forbes2022Rating>
        <Industries>
            <Industry>Biotechnology</Industry>
            <Industry>Medicine</Industry>
        </Industries>
        <FoundedYear>2008</FoundedYear>
        <Country>Germany</Country>
        <Region>Europe</Region>
        <KeyPersons>
            <Person>
                <Name>Ugur Sahin</Name>
                <founder>True</founder>
                <Ceo>True</Ceo>
                <other/>
            </Person>
            <Person>
                <Name>Ozlem Tureci</Name>
                <founder>True</founder>
                <Ceo>False</Ceo>
                <other/>
            </Person>
        </KeyPersons>
        <Revenue>17997279300</Revenue>
        <Assets>14569226100</Assets>
        <Profit>349375755.3</Profit>
        <MarketValue>100000000000</MarketValue>
        <SizeEmployees>5000</SizeEmployees>
        <SizeCategory>small company</SizeCategory>
        <LegalType>AG</LegalType>
        <SustGoalDescription>Target was approved using...</SustGoalDescription>
        <SustGoalStatus_NearTerm>Targets Set</SustGoalStatus_NearTerm>
        <SustGoalStatus_LongTerm>Targets Set</SustGoalStatus_LongTerm>
        <SustGoalClassification_NearTerm>Well-below 2°C</SustGoalClassification_NearTerm>
        <SustGoalClassification_LongTerm>Well-below 2°C</SustGoalClassification_LongTerm>
        <SustGoalYear_NearTerm>2030</SustGoalYear_NearTerm>
        <SustGoalYear_LongTerm>2050</SustGoalYear_LongTerm>
        <NetZeroCommitted>True</NetZeroCommitted>
        <NetZeroCommittedYear>2050</NetZeroCommittedYear>
    </Company>
    <Company>
        ...
    </Company>
</Companies>


            

